Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study.
Saved in:
| Title: | Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered as a booster to adults aged ≥59 years: A phase III randomized study. |
|---|---|
| Authors: | Robertson CA; Scientific & Medical Affairs, Sanofi, Swiftwater, PA, USA., Jacqmein J; Jacksonville Center for Clinical Research, Jacksonville, FL, USA., Selmani A; Biostatistics, Sanofi, Swiftwater, PA, USA., Galarza K; Scientific & Medical Affairs, Sanofi, Swiftwater, PA, USA., Oster P; Global Medical Affairs, Sanofi, Lyon, France. |
| Source: | Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2023 Dec 31; Vol. 19 (1), pp. 2160600. Date of Electronic Publication: 2023 Jan 11. |
| Publication Type: | Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
